Yap Beow Keat, Dr.
Lecturer
B. Pharm. (Hons.)(USM)
M. Med. Sc. (UM)
Ph.D (Monash University, Australia)
J02 Room 129
School of Pharmaceutical Sciences
Tel : 604-6533888 Ext. 2207
-
FAR212/2: Principles of Medicinal Chemistry
-
FAR244/3: Basic Pharmacognosy and Phytochemistry
-
FAR341/4: Respiratory, Renal, Blood System and Therapy
-
FAR342/3: Cardiovascular System and Therapy (Coordinator)
-
FAR343/2: Gastrointestinal System and Therapy
Drug design and discovery (fragments, small molecules – synthetic/natural compounds, cyclic peptides, cyclic peptidomimetics) using computational and nuclear magnetic resonance (NMR)-based approaches, targeting protein-protein interactions and receptors involved in pathogenesis of diseases.
-
Computational Chemistry: Homology modelling, molecular dynamics simulations, docking, de novo drug design (small molecules, cyclic peptides) (SYBYL-X, Discovery Studio, Maestro, GROMACS, AutoDock, Glide)
- Biochemistry: Protein expression (in bacterial cell E.coli), purification (affinity chromatography, FPLC) and characterisation (SDS-PAGE, Western Blot, NMR, LC-MS)
- Medicinal chemistry: Synthesis (Fmoc-chemistry, solid-phase), purifications (RP-HPLC) and characterisations of peptides, cyclic peptides and peptidomimetics (LC-MS, NMR).
- Drug discovery: 1D and 2D-NMR methods in fragment-based drug discovery, characterisation of protein-ligand binding interactions (NMR, surface plasmon resonance)
-
Harjani, J. R., Yap, B. K., Leung, E. W., Lucke, A., Nicholson, S. E., Scanlon, M. J., Chalmers, D. K., Thompson, P. E., Norton, R.S., and Baell, J. B. (2016) Design, synthesis, and characterization of cyclic peptidomimetics of the inducible nitric oxide synthase binding epitope that disrupt the protein-protein interaction involving SPRY domain-containing suppressor of cytokine signaling box protein (SPSB) 2 and inducible nitric oxide synthase, J. Med. Chem. 59, 5799-5809.
-
Harjani, J. R., Yap, B. K., Norton, R. S. and Baell, J. B. (2016) An alternative approach to the synthesis of peptides containing a cystathionine bridge, Tetrahedron 72, 3256-3261.
-
Yap, B. K., Harjani, J. R., Leung, E. W., Nicholson, S. E., Scanlon, M. J., Chalmers, D. K., Thompson, P. E., Baell, J. B., and Norton, R. S. (2016) Redox-stable cyclic peptide inhibitors of the SPSB2-iNOS interaction, FEBS Lett. 590, 696-704.
-
Yap, B. K., Leung, E. W., Yagi, H., Galea, C. A., Chhabra, S., Chalmers, D. K., Nicholson, S. E., Thompson, P. E., and Norton, R. S. (2014) A potent cyclic peptide targeting SPSB2 protein as a potential anti-infective agent, J. Med. Chem. 57, 7006-7015.
-
Munusamy, V., Yap, B. K., Buckle, M. J. C., Doughty, S. W. and Chung, L. Y. (2013) Structure-based identification of aporphines with selective 5-HT2A receptor-binding activity. Chem. Biol. Drug Des. 81, 250–256.
-
Yap, B. K., Buckle, M. J. C. and Doughty, S. W. (2012) Homology modeling of the human 5-HT1A, 5-HT2A, D1, and D2 receptors: model refinement with molecular dynamics simulations and docking evaluation. J. Mol. Model. 18, 3639-3655.
- Gam, L. H., Mohamad, Z. S. Z., and Yap, B. K. (2010) A method to differentiate gelatin capsule of the porcine source from the bovine source, World Intellectual Property Organization, WO 2010131940 A1